Literature DB >> 19882675

Inactive Wnt/beta-catenin pathway in conventional high-grade osteosarcoma.

Yongping Cai1, Alexander B Mohseny, Marcel Karperien, Pancras C W Hogendoorn, Gengyin Zhou, Anne-Marie Cleton-Jansen.   

Abstract

Osteosarcoma is the most common malignant bone tumour, with a peak incidence in children and young adolescents, suggesting a role of rapid bone growth in its pathogenesis. The Wnt/beta-catenin pathway plays a crucial role in skeletal development and is indispensable for osteoblasts' lineage determination. Previous studies suggesting an oncogenic role for the Wnt/beta-catenin pathway in osteosarcoma were based on cytoplasmic staining of beta-catenin or the detection of one component of this pathway. However, those approaches are inappropriate to address whether the Wnt/beta-catenin pathway is functionally active. Therefore, in this study, we examined nuclear beta-catenin expression in 52 human osteosarcoma biopsies, 15 osteoblastomas (benign bone tumours), and four human osteosarcoma cell lines by immunohistochemistry. Furthermore, we modulated Wnt/beta-catenin pathway activity using a GIN (GSK3beta inhibitor) and evaluated its effect on cell growth and osteogenic differentiation. Absence of nuclear beta-catenin staining was found in 90% of the biopsies and all osteosarcoma cell lines, whereas strong nuclear beta-catenin staining was observed in all osteoblastomas. Wnt-luciferase activity was comparable to the negative control in all osteosarcoma cell lines. GIN stimulated the Wnt/beta-catenin pathway, as shown by translocation of beta-catenin into the nucleus and increased Wnt-luciferase activity as well as mRNA expression of AXIN2, a specific downstream target gene. Stimulation of the Wnt/beta-catenin pathway by GIN significantly reduced cell proliferation in the cell lines MG-63 and U-2-OS and enhanced differentiation in the cell lines HOS and SJSA-1, as shown by an increase in alkaline phosphatase (ALP) activity and mineralization. In contrast with the oncogenic role of the Wnt/beta-catenin pathway in osteosarcoma as previous studies suggested, here we demonstrate that this pathway is inactivated in osteosarcoma. Moreover, activation of the Wnt/beta-catenin pathway inhibits cell proliferation or promotes osteogenic differentiation in osteosarcoma cell lines. Our data suggest that loss of Wnt/beta-catenin pathway activity, which is required for osteoblast differentiation, may contribute to osteosarcoma development.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19882675     DOI: 10.1002/path.2628

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  72 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

Review 2.  Osteoanabolic and dual action drugs.

Authors:  Gaia Tabacco; John P Bilezikian
Journal:  Br J Clin Pharmacol       Date:  2019-04-03       Impact factor: 4.335

Review 3.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

4.  Influence of β-catenin small interfering RNA on human osteosarcoma cells.

Authors:  Fan Zhang; Anmin Chen; Jianfeng Chen; Tian Yu; Fengjing Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-06-14

5.  Role of non-canonical Wnt signaling in osteoblast maturation on microstructured titanium surfaces.

Authors:  Rene Olivares-Navarrete; Sharon L Hyzy; Daphne L Hutton; Ginger R Dunn; Christoph Appert; Barbara D Boyan; Zvi Schwartz
Journal:  Acta Biomater       Date:  2011-02-23       Impact factor: 8.947

6.  Role of the WWOX tumor suppressor gene in bone homeostasis and the pathogenesis of osteosarcoma.

Authors:  Sara Del Mare; Kyle C Kurek; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  Am J Cancer Res       Date:  2011-04-03       Impact factor: 6.166

7.  Sclerostin expression in skeletal sarcomas.

Authors:  Jia Shen; Carolyn A Meyers; Swati Shrestha; Arun Singh; Greg LaChaud; Vi Nguyen; Greg Asatrian; Noah Federman; Nicholas Bernthal; Fritz C Eilber; Sarah M Dry; Kang Ting; Chia Soo; Aaron W James
Journal:  Hum Pathol       Date:  2016-08-03       Impact factor: 3.466

Review 8.  Wnt/β-catenin pathway in bone cancers.

Authors:  Jian Tian; Hongbo He; Guanghua Lei
Journal:  Tumour Biol       Date:  2014-08-13

9.  High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A.

Authors:  Sapna Vijayakumar; Guizhong Liu; Ioana A Rus; Shen Yao; Yan Chen; Gal Akiri; Luca Grumolato; Stuart A Aaronson
Journal:  Cancer Cell       Date:  2011-05-17       Impact factor: 31.743

10.  Profiling of high-grade central osteosarcoma and its putative progenitor cells identifies tumourigenic pathways.

Authors:  A-M Cleton-Jansen; J K Anninga; I H Briaire-de Bruijn; S Romeo; J Oosting; R M Egeler; H Gelderblom; A H M Taminiau; P C W Hogendoorn
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.